HK1210960A1 - Cyclodextrin for the treatment of lysosomal storage diseases - Google Patents

Cyclodextrin for the treatment of lysosomal storage diseases

Info

Publication number
HK1210960A1
HK1210960A1 HK15111861.6A HK15111861A HK1210960A1 HK 1210960 A1 HK1210960 A1 HK 1210960A1 HK 15111861 A HK15111861 A HK 15111861A HK 1210960 A1 HK1210960 A1 HK 1210960A1
Authority
HK
Hong Kong
Prior art keywords
cyclodextrin
treatment
lysosomal storage
storage diseases
diseases
Prior art date
Application number
HK15111861.6A
Other languages
English (en)
Chinese (zh)
Inventor
John Mckew
Wei Zheng
Miao Xu
Manju Swaroop
Juan J Marugan
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of HK1210960A1 publication Critical patent/HK1210960A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15111861.6A 2012-08-03 2015-12-02 Cyclodextrin for the treatment of lysosomal storage diseases HK1210960A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261679668P 2012-08-03 2012-08-03
PCT/US2013/053527 WO2014022841A1 (en) 2012-08-03 2013-08-03 Cyclodextrin for the treatment of lysosomal storage diseases

Publications (1)

Publication Number Publication Date
HK1210960A1 true HK1210960A1 (en) 2016-05-13

Family

ID=49170855

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15111861.6A HK1210960A1 (en) 2012-08-03 2015-12-02 Cyclodextrin for the treatment of lysosomal storage diseases

Country Status (8)

Country Link
US (2) US20150216895A1 (he)
EP (1) EP2879714B1 (he)
JP (3) JP2015524444A (he)
CN (2) CN107865968B (he)
AU (2) AU2013296170A1 (he)
CA (1) CA2880880C (he)
HK (1) HK1210960A1 (he)
WO (1) WO2014022841A1 (he)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107865968B (zh) 2012-08-03 2021-03-05 美国政府(由卫生和人类服务部的部长所代表) 用于治疗溶酶体贮积症的环糊精
EP3078379B1 (en) 2013-12-05 2018-11-28 National University Corporation Kumamoto University Drug for the treatment of cholesterol accumulation disorders, and screening method for same
WO2015191931A1 (en) 2014-06-12 2015-12-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
CA2976449C (en) * 2015-02-11 2022-08-09 Icahn School Of Medicine At Mount Sinai Benzenesulfonamide upregulators of npc1 for neimann-pick disease and other lysosomal storage disorders
MX2017015879A (es) * 2015-06-10 2018-08-16 Vtesse Inc Composiciones de hidroxipropil beta-ciclodextrina y metodos.
JP2019504178A (ja) * 2016-01-21 2019-02-14 アテン・ポラス・ライフサイエンシズ シクロデキストリンを主体とするポリマー、その方法、組成物、及び応用
WO2018051298A1 (en) * 2016-09-19 2018-03-22 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
JPWO2018199287A1 (ja) * 2017-04-28 2020-03-12 国立大学法人京都大学 クリスタリン網膜症の処置および／または予防方法
CN111655291A (zh) * 2017-08-28 2020-09-11 阿斯德拉有限责任公司 环糊精在涉及磷脂失调的疾病和病症中的用途
JP2020535235A (ja) 2017-09-28 2020-12-03 アスデラ エルエルシー リン脂質の調節異常が関与する疾患および障害におけるシクロデキストリンの使用
BR112021008139A2 (pt) 2018-10-29 2021-08-03 Cyclo Therapeutics, Inc. métodos para tratar doença de alzheimer
JP2022518147A (ja) 2019-01-03 2022-03-14 アンダードッグ・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン二量体、それらの組成物、及びそれらの使用
JP7264452B2 (ja) * 2019-04-15 2023-04-25 塩水港精糖株式会社 ライソゾーム病の治療または予防のための医薬組成物
US20230310490A1 (en) * 2020-09-03 2023-10-05 University Of Notre Dame Du Lac Therapy to stimulate hippocampal neural progenitors and adult neurogenesis
US11958917B2 (en) 2022-02-18 2024-04-16 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5262404A (en) 1990-02-15 1993-11-16 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
EP0803243B1 (en) 1996-04-24 2003-03-19 Pfizer Inc. Cyclodextrins and phenolic compounds in dental products
FR2767834B1 (fr) 1997-08-29 1999-12-03 Inst Francais Du Petrole Mono et di-derives de cyclodextrines, leurs synthese et purification et leur utilisation en support
WO2001087360A2 (en) 2000-05-15 2001-11-22 The Procter & Gamble Company Compositions comprising cyclodextrin derivatives
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2005112637A1 (en) * 2004-05-14 2005-12-01 Decode Chemistry, Inc. Formulations for non-parenteral use including hydrophobic cyclodextrins
EP1655034A1 (en) 2004-10-10 2006-05-10 Université de Liège Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases.
US20090258001A1 (en) * 2006-06-06 2009-10-15 Paul Ponath Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
US20120077774A1 (en) * 2009-05-28 2012-03-29 Cornell University Compositions and their use for removing cholesterol
EP2595623B1 (en) * 2010-07-19 2018-02-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
US10463687B2 (en) * 2011-01-20 2019-11-05 Cornell University Treatments for retinal disorders
CN107865968B (zh) 2012-08-03 2021-03-05 美国政府(由卫生和人类服务部的部长所代表) 用于治疗溶酶体贮积症的环糊精
FR3014694B1 (fr) 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl

Also Published As

Publication number Publication date
JP2020097620A (ja) 2020-06-25
EP2879714B1 (en) 2021-04-14
JP2015524444A (ja) 2015-08-24
JP2018162277A (ja) 2018-10-18
US20180110798A1 (en) 2018-04-26
CA2880880C (en) 2021-01-26
EP2879714A1 (en) 2015-06-10
CA2880880A1 (en) 2014-02-06
US11020422B2 (en) 2021-06-01
CN107865968A (zh) 2018-04-03
AU2013296170A1 (en) 2015-03-12
JP6858286B2 (ja) 2021-04-14
WO2014022841A1 (en) 2014-02-06
US20150216895A1 (en) 2015-08-06
CN107865968B (zh) 2021-03-05
AU2018202964B2 (en) 2019-08-22
CN104684585A (zh) 2015-06-03
AU2018202964A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
IL271651B (he) צנתר המותאם למגע ישיר עם רקמה
HK1210960A1 (en) Cyclodextrin for the treatment of lysosomal storage diseases
HK1209788A1 (en) Methods and compositions for the treatment of lysosomal storage diseases
IL263661A (he) טיפול משולב לטיפול בגליובלסטומה
EP2921192A4 (en) CATHETER
EP2823767A4 (en) CATHETER
EP2906208A4 (en) THERAPEUTIC TREATMENT
EP2926857A4 (en) CATHETER
EP2928536A4 (en) TRANSCATHETER AORTIC VALVULE VENTRICULAR REPLACEMENT CATHETER (TAVR)
EP2863983B8 (en) Medical therapy arrangement
EP2832398A4 (en) MEDICAL SHUTTER
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
HK1204605A1 (en) Functionalized thieno-indole derivatives for the treatment of cancer
EP2898871A4 (en) MEDICAL CONTAINER
EP2821073A4 (en) CIRCADIAN RHYTHM IMPROVEMENT AGENT
PT2872176T (pt) Carboranilporpirinas para utilização no tratamento de cancro
EP2810680A4 (en) CATHETER
EP2914267A4 (en) TREATMENT OF DARM CONSTIPATION
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
IL234796B (he) תרכובות לטיפול במחלות הקשורות לאיסכמיה–רפרפוזיה
GB201322272D0 (en) Catheter and process for cleaning the catheter
EP2898872A4 (en) MEDICAL CONTAINER
EP2900310A4 (en) MULTI-WINDING CATHETER
AU2012900513A0 (en) Avian-Based Treatment
GB201211135D0 (en) Treatment